|
|
|
21 Sep 2007 |
Vical Licensee Sanofi-aventis Initiates Phase 3 Trial to Reduce Amputations
|
|
19 Sep 2007 |
LigoCyte Pharmaceuticals Announces Collaboration With Biogen Idec to Develop Anti-CD103 Therapies
|
|
19 Sep 2007 |
Antitope Announces Research Agreement with Fraunhofer Institute for Cell Therapy and Immunology
|
|
14 Sep 2007 |
Genmab Discloses Target and Development Plans for HuMax-Inflam
|
|
14 Sep 2007 |
Genmab Provides Insights into IgG4 Antibodies
|
|
13 Sep 2007 |
DAHANCA Initiates Head and Neck Cancer Study with Genmab's HuMax-EGFr
|
|
13 Sep 2007 |
XOMA Initiates Phase 1 European Trial in Diabetes for XOMA 052, a Novel Anti-IL-1 Antibody Designed to Target Diabetes, Rheumatoid Arthritis and Other Inflammatory Diseases
|
|
12 Sep 2007 |
Astellas Initiates Phase II Clinical Trials for Immunosuppressant, ASP0485
|
|
11 Sep 2007 |
Merck: Erbitux Phase III Study - FLEX Increases Overall Survival in First-line Treatment of Non-Small Cell Lung Cancer
|
|
11 Sep 2007 |
Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis
|
|
08 Sep 2007 |
Ablynx and Boehringer Ingelheim announce major global strategic alliance to discover, develop and commercialise novel nanobody(R) therapeutics
|
|
08 Sep 2007 |
ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402
|
|
08 Sep 2007 |
Genmab announces encouraging preclinical data for Ofatumumab
|
|
06 Sep 2007 |
Medarex Announces Extension of Broad Antibody Development Relationship with Centocor
|
|
06 Sep 2007 |
Dyax Corp. and Bayer Schering Pharma AG Enter Into a Collaboration Agreement for Discovery of Therapeutic Antibodies
|
|
06 Sep 2007 |
Access and Somanta Announce New Data on Angiolix(R) Humanized Monoclonal Antibody
|
|
05 Sep 2007 |
YM BioSciences Announces positive preliminary results from Phase I/II lung cancer trial of nimotuzumab combined with radiation
|
|
05 Sep 2007 |
Lpath Demonstrates Preclinical Efficacy of Lpathomab(TM) and Initiates Humanization Process
|
|
04 Sep 2007 |
Merck Applies to Extend Use of Erbitux(R) for 1st-Line Colorectal Cancer
|
|
31 Aug 2007 |
YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
|
|
30 Aug 2007 |
Merck Serono to Reconsider Development of Matuzumab in Metastatic Colorectal Cancer Patients
|
|
29 Aug 2007 |
Phase II Study of IMC-A12 for Advanced Prostate Cancer Commences Patient Enrollment
|
|
29 Aug 2007 |
Baxter and the Alzheimer's Disease Cooperative Study Group to Pursue a Phase III Study of Gammagard Liquid in Patients with Alzheimer's Disease
|
|
29 Aug 2007 |
XOMA Licenses Antibody Technology to Pfizer
|
|
25 Aug 2007 |
Phase II study of IMC-1121B for advanced renal cell cancer opens for patient enrollment
|
|
25 Aug 2007 |
Avastin approved in Europe for first-line treatment of patients with advanced lung cancer
|
|
25 Aug 2007 |
Genentech announces resubmission of supplemental Biologics License Application for Avastin in combination with Paclitaxel for first-line metastatic breast cancer
|
|
24 Aug 2007 |
Phase 3 Oncology Program for Aflibercept (VEGF Trap) Initiated
|
|
23 Aug 2007 |
MedImmune's motavizumab reduced RSV hospitalizations by 83 percent among high-risk native American, full-term infants in placebo-controlled Phase 3 study
|
|
22 Aug 2007 |
YM BioSciences', European partner, Oncoscience AG, announces initiation of advanced nimotuzumab trials in adult glioma and pancreatic cancer
|
|
22 Aug 2007 |
Protox acquires research program from Medicenna
|
|
21 Aug 2007 |
Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
|
|
21 Aug 2007 |
PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials
|
|
17 Aug 2007 |
Auxilium Pharmaceuticals, Inc. receives clearance to resume clinical trials for XIAFLEX(TM)
|
|
16 Aug 2007 |
Anadis to use its polyclonal antibodies for treatment
|
|
16 Aug 2007 |
Cell Therapeutics, Inc. (CTI) enters agreement to acquire lymphoma drug Zevalin(R) from Biogen Idec for sales and marketing in the United States
|
|
15 Aug 2007 |
Oncoscience AG, the european partner of YM BioSciences, announces completion of patient enrollment in phase III brain cancer trial of nimotuzab
|
|
10 Aug 2007 |
Roche files IND for second Genmab antibody
|
|
10 Aug 2007 |
Rilonacept (IL-1 Trap) granted FDA priority review for the treatment of CAPS
|
|
09 Aug 2007 |
ORENCIA(R) (abatacept) supplemental biologics license application for juvenile idiopathic arthritis accepted by FDA for filing and review
|
|
09 Aug 2007 |
InNexus Biotechnology unveils new platform for augmenting antibody therapeutics
|
|
08 Aug 2007 |
Intellect Neurosciences, Inc. and Medical Research Council Technology (U.K.) Enter into Agreement to Humanize Two Monoclonal Antibodies for the Treatment of Alzheimer's Disease
|
|
04 Aug 2007 |
Bayer HealthCare and Regeneron initiate Phase 3 global development program for VEGF Trap-Eye in wet age-related macular degeneration (AMD)
|
|
03 Aug 2007 |
Genmab regains rights to HuMax-TAC
|
|
03 Aug 2007 |
Macrogenics Begins Global Phase 2/3 Protege Study In Recent-onset Type 1 Diabetes Mellitus
|
|
02 Aug 2007 |
ImmunoGen, Inc. Initiates Phase II Clinical Trial of HuC242-DM4
|
|
02 Aug 2007 |
Phase 2a Multi-dose Study Initiated By Medimmune In Patients With Asthma To Further Expand Anti-interleukin-9 Program
|
|
01 Aug 2007 |
ImmunoGen, Inc. Earns Milestone with Start of Trastuzumab-DM1 Phase II Testing
|
|
01 Aug 2007 |
Preliminary Data Add New Mechanistic Insights to Activity of Anthrax Anti-Toxin, Valortim(TM)
|
|
01 Aug 2007 |
YM BioSciences initiates patient enrolment in phase II colorectal cancer trial with EGFR antibody
|
| |
|
Results 501 - 550 of 1155 |
